Virpax Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VRPX Nasdaq 8731 https://virpaxpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments - May 12th, 2023 8:08 pm
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar - May 10th, 2023 11:15 am
Sidoti's Micro-Cap Virtual May Conference - May 9th, 2023 11:15 am
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023 - May 4th, 2023 12:58 pm
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™ - Apr 27th, 2023 12:58 pm
Virpax Reports on Progress of Envelta™ - Apr 5th, 2023 12:58 pm
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors - Mar 28th, 2023 12:58 pm
Virpax Pharmaceuticals Reports 2022 Year-End Results - Mar 22nd, 2023 12:58 pm
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET) - Feb 13th, 2023 1:58 pm
Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China - Jan 31st, 2023 1:58 pm
Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™ - Jan 18th, 2023 2:00 pm
Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts - Jan 10th, 2023 2:00 pm
Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324) - Jan 4th, 2023 2:00 pm
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324) - Dec 14th, 2022 2:00 pm
Virpax Pharmaceuticals Reports 2022 Third Quarter Results - Nov 9th, 2022 2:00 pm
Quite a few insiders invested in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) last year which is positive news for shareholders - Oct 13th, 2022 10:29 am
Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain - Aug 24th, 2022 1:00 pm
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments - Aug 15th, 2022 1:00 pm
Virpax Pursues OTC Medical Device Pathway for AnQlar™ - Jul 5th, 2022 1:00 pm
These summer travel destinations are on sale right now - Jul 1st, 2022 8:04 pm